Exchange Announcement • 03 Jun 2026 18:57
Exchange Announcement • 02 Jun 2026 19:59
Exchange Announcement • 01 Jun 2026 18:54
Exchange Announcement • 28 May 2026 17:55
Exchange Announcement • 26 May 2026 18:27
𝛼SK or SearchENTITY
Jacobio Pharmaceuticals (1167 HK)
Jacobio Pharmaceuticals (1167 HK)
74
Analysis
Health Care • China
Jacobio Pharmaceuticals is a clinical-stage pharmaceutical company dedicated to the in-house discovery and development of innovative oncology therapies, focusing on "undruggable" targets in key oncogenic pathways. They leverage their Induced Allosteric Molecule Discovery Platform and iADC Platform to develop novel drugs, including clinical-stage candidates like Glecirasib (KRAS G12C inhibitor) and Sitneprotafib (SHP2 inhibitor) for various solid tumors. The company was founded in 2015 and is headquartered in Beijing, China.
morex